Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2023
Haihe Biopharma announces gumarontinib receives approval from the NMPA of China for the treatment of locally advanced or metastatic NSCLC with MET exon 14 skipping mutation
8 March 2023 - Haihe Biopharma today announced that the NMPA of China has given conditional approval to gumarontinib, an oral ...
Posted by Michael Wonder on 10 Mar 2023
Astellas and Seagen announce China's National Medical Products Administration accepts biologics license application for enfortumab vedotin in certain patients with locally advanced or metastatic urothelial cancer
10 March 2023 - Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option ...
Posted by Michael Wonder on 28 Feb 2023
CStone announces China’s NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastro-oesophageal junction adenocarcinoma
28 February 2023 - This supplementary new drug application was filed for the fourth indication for sugemalimab in China, following applications ...
Posted by Michael Wonder on 28 Feb 2023
Biologics license application for lecanemab designated for priority review by China NMPA
28 February 2023 - Eisai and Biogen announced today that the biologics license application for lecanemab (brand name in the US: ...
Posted by Michael Wonder on 24 Feb 2023
Enhertu approved in China for patients with HER2 positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
24 February 2023 - First approval for AstraZeneca and Daiichi Sankyo’s Enhertu in China. ...
Posted by Michael Wonder on 06 Feb 2023
China’s 2022 NRDL readout
7 February 2023 - Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement ...
Posted by Michael Wonder on 03 Feb 2023
Zai Lab announces NDA for sulbactam-durlobactam granted priority review by China’s NMPA
30 January 2023 - Zai Lab today announced that the Center for Drug Evaluation of China’s National Medical Products Administration has ...
Posted by Michael Wonder on 01 Feb 2023
Simcere’s COVID-19 pill goes on sale in China at less than half the price of Pfizer’s Paxlovid
31 January 2023 - The retail price of Simcere Pharmaceutical’s orally taken COVID-19 treatment, which was only approved to go ...
Posted by Michael Wonder on 30 Jan 2023
Alpha Biopharma submits new drug application for zorifertinib, a next generation EGFR-TKI to treat EGFR mutated NSCLC patients with CNS metastases
30 January 2023 - Alpha Biopharma announces that the Center for Drug Evaluation of the NMPA has accepted its new drug ...
Posted by Michael Wonder on 30 Jan 2023
Junshi Biosciences announces approval for marketing of VV116 in China
30 January 2023 - Shanghai Junshi Biosciences announced today that the NMPA has conducted urgent review and approval under special examination ...
Posted by Michael Wonder on 23 Jan 2023
China’s drug pricing policy impedes biotech profits
23 January 2023 - Beijing’s push to boost the sector has been undermined by reimbursement rules. ...
Posted by Michael Wonder on 21 Jan 2023
RemeGen announces two indications for anti-HER2 antibody drug conjugate disitamab vedotin included in China's National Reimbursement Drug List for 2023
20 January 2023 - RemeGen is pleased to announce that as of 18 January 2023, two indications for the Company's ...
Posted by Michael Wonder on 21 Jan 2023
China's first and only approved third generation BCR-ABL inhibitor olverembatinib included into the 2022 National Reimbursement Drug List
18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the ...
Posted by Michael Wonder on 19 Jan 2023
Drugs added to reimbursement list
19 January 2023 - China will add 111 drugs to its national medical reimbursement list this year, with a focus ...
Posted by Michael Wonder on 19 Jan 2023
Innovent announces inclusion in the China National Reimbursement Drug List of Tyvyt in two new indications, olverembatinib for the first listing, Byvadsa, Halpryza and Sulinno in multiple new indications
18 January 2023 - Innovent Biologics today announced that, five products (including new indications) of the company have been included in ...